308 related articles for article (PubMed ID: 21256633)
1. [Injection of botulinum toxin (BTX-A) in children with bladder dysfunction due to detrusor overactivity].
Romero RM; Rivas S; Parente A; Fanjul M; Angulo JM
Actas Urol Esp; 2011 Feb; 35(2):89-92. PubMed ID: 21256633
[TBL] [Abstract][Full Text] [Related]
2. Intravesical electromotive botulinum toxin type A administration--part II: Clinical application.
Kajbafzadeh AM; Ahmadi H; Montaser-Kouhsari L; Sharifi-Rad L; Nejat F; Bazargan-Hejazi S
Urology; 2011 Feb; 77(2):439-45. PubMed ID: 20800886
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial.
Abdel-Meguid TA
J Urol; 2010 Dec; 184(6):2423-8. PubMed ID: 20952003
[TBL] [Abstract][Full Text] [Related]
5. Prolonged urinary retention after intravesical botulinum injection for treatment of idiopathic detrusor overactivity.
King AB; Rapp DE
Can J Urol; 2011 Apr; 18(2):5657-9. PubMed ID: 21504656
[TBL] [Abstract][Full Text] [Related]
6. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome.
Kuo HC; Liao CH; Chung SD
Eur Urol; 2010 Dec; 58(6):919-26. PubMed ID: 20864251
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis.
Khan S; Game X; Kalsi V; Gonzales G; Panicker J; Elneil S; Apostolidis A; Hamid R; Dasgupta P; Kessler TM; Fowler CJ
J Urol; 2011 Apr; 185(4):1344-9. PubMed ID: 21334639
[TBL] [Abstract][Full Text] [Related]
8. [Input from a specialized nurse consultation in the management of detrusor overactivity treated with intradetrusor injections of botulinum toxin in urology department. Pilot study].
Le Gal S; Safsaf A; Galliot I; Catovic B; Grise P
Prog Urol; 2010 Sep; 20(8):584-9. PubMed ID: 20832036
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses.
Grise P; Ruffion A; Denys P; Egon G; Chartier Kastler E
Eur Urol; 2010 Nov; 58(5):759-66. PubMed ID: 20674149
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
[TBL] [Abstract][Full Text] [Related]
11. Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.
Al Edwan GM; Mansi HH; Atta ONM; Shaath MM; Al Adwan R; Mahafza W; Afram KM; Ababneh O; Al Adwan D; Muheilan MM
J Pediatr Surg; 2019 Mar; 54(3):595-599. PubMed ID: 29887168
[TBL] [Abstract][Full Text] [Related]
12. Antibodies after botulinum toxin A injection into musculus detrusor vesicae: incidence and clinical relevance.
Hegele A; Frohme C; Varga Z; Olbert P; Kranz J; Hofmann R
Urol Int; 2011; 87(4):439-44. PubMed ID: 22004911
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder: early outcomes.
Okamura K; Nojiri Y; Ameda K; Namima T; Suzuki M; Inoue K; Ogawa T; Gotoh M; Homma Y
Int J Urol; 2011 Jun; 18(6):483-7. PubMed ID: 21488978
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
[TBL] [Abstract][Full Text] [Related]
15. Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study.
Lahdes-Vasama TT; Anttila A; Wahl E; Taskinen S
Scand J Urol Nephrol; 2011 Dec; 45(6):397-400. PubMed ID: 21740110
[TBL] [Abstract][Full Text] [Related]
16. Intravesical botulinum type-A toxin (Dysport®) in the treatment of idiopathic detrusor overactivity in children.
Blackburn SC; Jones C; Bedoya S; Steinbrecher HA; Malone PS; Griffin SJ
J Pediatr Urol; 2013 Dec; 9(6 Pt A):750-3. PubMed ID: 23036518
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin treatment for bladder dysfunction.
Santos-Silva A; da Silva CM; Cruz F
Int J Urol; 2013 Oct; 20(10):956-62. PubMed ID: 23634720
[TBL] [Abstract][Full Text] [Related]
18. Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
Kantartzis K; Shepherd J
Curr Opin Obstet Gynecol; 2012 Oct; 24(5):331-6. PubMed ID: 22922403
[TBL] [Abstract][Full Text] [Related]
19. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity.
Sahai A; Dowson C; Khan MS; Dasgupta P;
Urology; 2010 Mar; 75(3):552-8. PubMed ID: 20035984
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin injection: a review of injection principles and protocols.
Rapp DE; Lucioni A; Bales GT
Int Braz J Urol; 2007; 33(2):132-41. PubMed ID: 17488531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
